

Peter I. Folb

Drug Safety in Clinical Practice

Peter I. Folb

Drug Safety in Clinical Practice

With 24 Figures

Springer-Verlag
Berlin Heidelberg New York Tokyo
1984

Peter I. Folb, MD, FRCP

Professor of Pharmacology,
University of Cape Town Medical School;
Chief Physician, Groote Schuur Hospital,
Cape Town.

ISBN 3-540-12811-5 Springer-Verlag Berlin Heidelberg New York Tokyo
ISBN 0-387-12811-5 Springer-Verlag New York Heidelberg Berlin Tokyo

Library of Congress Cataloging in Publication Data

Folb, Peter I., 1938- . Drug safety in clinical practice.

Bibliography: p. Includes index. 1. Drugs - Safety measures. 2. Drugs - Side effects. I. Title RM301.F57 1983 615'.704283-17156

ISBN 0-387-12811-5 (U.S.)

This work is subject to copyright. All rights reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying, machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use, a fee is payable to "Verwertungsgesellschaft Wort", Munich.

© by Springer-Verlag Berlin Heidelberg, 1984
Printed in Great Britain

The use of general descriptive names, trade marks, etc. in this publication, even if the former are not to be taken as a sign that such names, as understood by the Trade Marks and Merchandise Marks Act, may accordingly be used freely by anyone.

Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Filmset by Input Typesetting Limited, London, SW19 8DR
Printed by Robert Hartnoll Ltd, Bodmin, Cornwall.

2128/3916-543210

Preface

Drugs may cause disease, or they may aggravate the morbidity of the condition for which they are prescribed, and certain patients may for one or other reason be particularly liable to drug injury. The inextricable relationships between the toxic profiles of drugs, the natural history of the diseases for which they are given, and the adverse drug effects that may develop in the course of such diseases are of considerable interest. It is the study of these rather neglected aspects of pharmacology and therapeutics which has formed the basis of this book.

An explanation is required of the approach and the style which have been followed. The monograph does not purport to be comprehensive. Only important drug groups which are commonly used in practice are considered. Emphasis has been placed on achieving maximum benefit and safety of the appropriate drugs in the management of common illnesses. When treatment fails, either *ab initio* or subsequent to an initial response, the risk-benefit relationship of drugs inevitably alters. For this reason the main factors responsible for treatment failure have been considered, with special attention to the possible contribution of or implications for drug therapy in such a situation. Finally, proposals have been put forward for improving the diagnosis and reporting of adverse drug effects.

In order to be practical and, as far as possible, constructive it has been necessary for me to "take a position" on numerous issues. In many instances I have expressed a point of view based on my understanding of authoritative literature (cited at the end of each section) and such clinical experience as I may have gained or have accrued from colleagues. There is a danger that this approach will be seen as somewhat categorical. I hope, however, that it may be understood as an attempt to depart from the descriptive and encyclopaedic approach which has tended to characterise medical writing in this particular field.

My colleagues John Straughan and Ashley Robins have in particular given me helpful advice, and I am grateful to Michael Jackson of Springer-Verlag who has guided the original idea behind

the book to fruition. Renée Gelbart and June Chambers have given me much assistance in the compilation of material. Elise Fuller helped with the illustrations. The Medicines Safety Centre of the University of Cape Town Medical School, jointly sponsored by Ciba Geigy, has been a source of valuable information.

The South African Medical Research Council and the University of Cape Town have supported my researches into mechanisms and models of drug-induced damage, and this help is gratefully acknowledged.

Cape Town, 1983

Peter I. Folb

Contents

| | |
|---|----|
| 1 Drugs in Common Use | 1 |
| 1.1 Antibiotics | 1 |
| Topical antibiotics; beta-lactamases; side-effects; renal elimination; hepatic disease and failure | |
| 1.2 Antihistamines | 9 |
| Use in the common cold and upper respiratory tract infections; special problems; interaction with other drugs; adverse effects on the nervous system; topical use; acute poisoning | |
| 1.3 Histamine ₂ -Receptor Blocking Agents | 13 |
| Cimetidine; ranitidine | |
| 1.4 Antacids | 16 |
| Aluminium toxicity; chronic aluminium toxicity; bismuth encephalopathy and neuropathy | |
| 1.5 Laxatives | 19 |
| Safety profiles; cathartic syndrome; chronic hypokalaemia; mineral oil deposits; phenolphthalein | |
| 1.6 Antidiarrhoeal Agents | 22 |
| Kaolin; pectin; bismuth, anticholinergics; opiates; diphenoxylate and atropine; iodochlorhydroxyquin; antidiarrhoeal/antibiotic combinations | |
| 1.7 Aspirin and the Acidic Non-steroidal Anti-inflammatory Agents | 25 |
| Gastrointestinal injury; sensitivity reactions; analgesic nephropathy; redistributional drug interactions; general considerations for use in chronic rheumatic conditions | |
| 1.8 Digitalis | 30 |
| Clinical signs of digitalis toxicity; early recognition of cardiotoxicity; contraindications to digitalis therapy; massive digitalis intoxication; digoxin and quinidine | |

| | |
|--|----|
| 1.9 Sympathomimetic Drugs | 33 |
| Adrenaline; ephedrine; phenylpropanolamine; noradrenaline; isoprenaline; beta ₂ -selective agents; dopamine and dobutamine; clonidine | |
| 1.10 Alpha-Adrenoreceptor Blocking Agents | 37 |
| Phenoxybenzamine; prazosin; indoramin | |
| 1.11 Beta-Adrenoreceptor Blocking Agents | 39 |
| 1.12 Potassium Supplements | 40 |
| 1.13 Nitrates | 41 |
| Adverse Effects; Tolerance | |
| 1.14 Calcium Antagonists | 42 |
| Verapamil; nifedipine; perhexilene; prenylamine; diltiazem | |
| 1.15 Benzodiazepines | 44 |
| Guidelines for use; dependence | |
| 1.16 Tricyclic Antidepressants | 46 |
| Cardiotoxicity; postural hypotension; anticholinergic effects; epilepsy; acute withdrawal effects | |
| 1.17 Methylphenidate | 49 |
| 1.18 Anorectic Agents | 50 |
| Sympathomimetic amines; safety; fenfluramine; phenylpropanolamine; comparative pharmacological effects | |
| 1.19 Addition of Drugs to Intravenous Fluids | 55 |
| 1.20 Parenteral Nutrition | 57 |
| Micronutrient deficiencies; metabolic bone disease; hepatic dysfunction; fat overload syndrome | |
| 1.21 Topical Corticosteroids | 61 |
| Potency; activity; local toxicity; systemic toxicity; minimising risks of adverse effects; use in ophthalmology | |
| 1.22 Methylene Blue | 65 |
| Use in methaemoglobinaemia; toxicity | |
| 1.23 Vitamins | 66 |
| Vitamin A (retinol): requirements; hypervitaminosis A | |
| Vitamin B ₁₂ and folic acid | |
| Vitamin C: antiscorbutic activity; toxicity | |
| Vitamin D: Normal requirements; individual susceptibility; hypervitaminosis D | |
| Vitamin K: adverse effects; treatment of hypoprothrombinaemia | |

| | |
|--|-----------|
| 2 Drug Safety in Some Common Medical Conditions | 73 |
| 2.1 Heart Failure | 73 |
| Excessive diuresis; diuretic escape; hypokalaemia; digitalis toxicity; myocardial ischaemia; adverse drug-drug interactions; lack of response to therapy | |
| 2.2 Hypertension | 77 |
| Stepped approach to drug treatment; captopril; methyldopa; beta-adrenoreceptor blocking agents; frusemide; prazosin; minoxidil; drug treatment in the elderly | |
| 2.3 Cough | 84 |
| Codeine; mucolytic agents; antihistamines | |
| 2.4 Bronchial Asthma | 87 |
| Methylxanthines; combination anti-asthmatic preparations | |
| 2.5 Tuberculosis and Other Mycobacterial Infections ... | 91 |
| Drugs of choice; treatment failure; toxicity profiles; renal failure; hepatotoxicity; pregnancy | |
| 2.6 Fungal Infections | 96 |
| Amphotericin B; 5-fluorocytosine | |
| 2.7 Malaria | 98 |
| Cerebral malaria; adverse effects of antimalarial agents; prophylaxis in pregnancy | |
| 2.8 Urinary Tract Infections | 101 |
| Antimicrobial therapy of uncomplicated infections; repeated infections; catheter-associated infections; treatment in renal failure; nalidixic acid; nitrofurantoin | |
| 2.9 Cancer Chemotherapy | 106 |
| Resistance to cytotoxic agents; general guidelines | |
| 2.10 Iron-Deficiency Anaemia | 112 |
| Contraindications to iron; failed response; choice of an oral iron preparation; adverse effects of oral therapy; hazards of parenteral therapy; iron supplements | |
| 2.11 Diabetes Mellitus | 115 |
| Insulin allergy; insulin lipodystrophy and lipohypertrophy; insulin resistance; insulin hypoglycaemic reactions; the Somogyi effect; beta- adrenoreceptor blocking drugs and blood sugar control; sulphonylureas; lactic acidosis; chlorpropamide-alcohol flush | |
| 2.12 Gout | 125 |
| Colchicine; indomethacin; uricosuric agents; allopurinol | |

| | | |
|------|---|-----|
| 2.13 | Myasthenia Gravis | 129 |
| | Anticholinesterases; atropine; corticosteroids; other drugs affecting the myoneuronal junction | |
| 3 | Patients at Special Risk | 135 |
| 3.1 | Pregnant Women | 135 |
| | Drug injury to the fetus: drug usage in pregnancy Drug treatment of important medical conditions in pregnancy: severe vomiting and hyperemesis gravidarum; epilepsy; rheumatic conditions; tuberculosis; ulcerative colitis; anticoagulation; depression | |
| 3.2 | Breast-Feeding mothers | 141 |
| 3.3 | The Elderly | 144 |
| | Disinhibition reactions; neuropsychiatric syndromes; tranquilliser dependence; anticholinergic syndrome; hypoglycaemic syndromes; ocular effects; special issues in drug treatment; guidelines | |
| 3.4 | Motor Vehicle Drivers | 149 |
| 3.5 | Porphyrics | 150 |
| | Clinical guidelines; management of an acute attack; prediction | |
| 4 | Drug Injuries | 155 |
| 4.1 | Drug Fever | 155 |
| | Causes; pathogenesis; clinical features; predisposing factors; diagnosis; management; Herxheimer reaction; malignant hyperthermia; neuroleptic malignant syndrome | |
| 4.2 | Anaphylaxis and Anaphylactoid Reactions | 159 |
| | Pathogenesis; symptomatology; prediction and prevention; differential diagnosis; Hoigne's syndrome; serum sickness reactions; classification of allergic drug reactions | |
| 4.3 | Drug-Induced Diseases of the Skin | 168 |
| | Diagnosis and natural history; management of hypersensitivity | |
| 4.4 | Drug-Induced Vasculitis | 171 |
| | Clinical features; allopurinol hypersensitivity | |
| 4.5 | Drug-Induced Vomiting | 173 |
| | Metoclopramide; cannabinoids | |
| 4.6 | Central Anticholinergic Syndromes | 175 |
| | Toxic confusional state; disorders of temperature control; neuroleptic malignant syndrome; physostigmine | |

| | |
|--|-----|
| Contents | xi |
| 4.7 Drug-Induced Ototoxicity | 178 |
| Diagnosis; aminoglycosides; salicylates; non-steroidal anti-inflammatory agents; antimalarials; loop diuretics | |
| 5 Diagnosing Adverse Drug Reactions | 181 |
| Classification; probability of association; severity; Berkson's bias | |
| Subject Index | 187 |

1 Drugs in Common Use

1.1 Antibiotics

The following *ground rules* for the use of antibiotics would contribute to optimising their benefit-risk relationships:

1. When adverse effects may have been experienced with previous antibiotic therapy, an alternative equally effective antibiotic of a different generic group is sought.
2. In selecting an antibiotic its clinical pharmacokinetics are considered, with special attention paid to transfer across the blood-brain barrier and distribution and elimination in renal failure and hepatic disease.
3. Combination therapy is administered only when a synergistic effect can be achieved. Unnecessary combination of antibiotics heightens the risks of toxicity, favours selection of resistant organisms, and represents additional expense, without contributing to a simpler regimen.
4. Bactericidal and bacteriostatic antibiotics are not combined (Table 1.1). This may result in a bacteriostatic effect alone, as the bactericidal activity of certain antibiotics is dependent upon rapid division of bacterial cells.
5. Antibiotics with similar toxicity profiles, which are known to cause adverse effects on the same organ, are not given together.
6. Antibiotic therapy for fever of undetermined origin is avoided as far as possible. Fever of several days' duration which is not associated with clinical signs of infection is usually due to viral infection, often of the respiratory tract, which will not respond to antibiotics. Prolonged fever, when it has an infectious cause, is most commonly due to tuberculosis or bacterial endocarditis. In either case blind use of antibiotics is likely to delay diagnosis and increase the risk of extensive damage.
7. The use of topical antibiotics (with the exception of use in the eye) is probably an important contributory factor to the development of antibiotic resistance of micro-organisms. Suitable alternatives may be effectively used for mild superficial infections. Severe skin infections are properly managed by systemic antibiotic therapy.

Table 1.1. Classification of antibiotics according to bactericidal or bacteriostatic activity (based on Reiner 1982)

| Group I: | Group II: | Group III: |
|---|---|--|
| Bactericidal, partially also on resting micro-organisms | Bactericidal, only on proliferating micro-organisms | Bacteriostatic, in high concentrations also bactericidal |
| Polymyxins | Penicillin | Chloramphenicol |
| Streptomycin | Cephalosporins | Thiamphenicol |
| Neomycin | Vancomycin | Tetracyclines |
| Kanamycin | Rifampicin | Fusidic acid |
| Gentamicin | | Erythromycin |
| Sisomicin | | Lincomycin |
| Netilmicin | | Clindamycin |
| Tobramycin | | |
| Amikacin | | |

Notes:

- The activity of an antibiotic combination can differ, depending on the components concerned, viz:

| | | |
|---------------------|---|--|
| <i>Indifference</i> | — | the activity of the combination is equal to that of the more active component. |
| <i>Addition</i> | — | the activity of the combination is equal to the sum of the activities of the components. |
| <i>Synergism</i> | — | the activity of the combination is significantly greater than the sum of the components. |
| <i>Antagonism</i> | — | the activity of the combination is less than that of the more active component. |
- The combination of antibiotics *within* groups I and II usually does not display antagonism.
- The combination of an antibiotic of group I with one of groups II or III rarely gives rise to antagonism. In general, the bactericidal agent predominates.
- The combination of an antibiotic of group II with one of group III frequently leads to dominance of the bacteriostatic agent, i.e. the activity of the combination corresponds to the activity of the agent of group III. Antagonism is possible.
- Prophylactic antibiotics, frequently given despite inadequate evidence that they are effective, may generate problems of toxicity and microbial resistance.
 The case for prophylaxis in rheumatic fever and bacterial endocarditis is established, and a good argument can be made for prophylaxis in meningococcal infections, diphtheria, to cover urological procedures, recurrent urinary tract infections, severe cases of chronic bronchitis, and patients with "healed" or "inactive" tuberculosis at special risk. Prophylactic antibiotics are widely used in hip replacement and vascular surgery.
- It is important that an antibiotic is selected which has the narrowest effective range for the micro-organism or micro-organisms responsible for the infection being treated. The antibacterial range of antibiotics in common use is indicated in Fig. 1.1. For severe infections, antibiotics are ideally administered parenterally in the first instance.

| Anaerobes | Gram-positive organisms | | Gram-negative organisms | |
|---------------|-------------------------------|---|-------------------------------|---|
| | streptococci | <div> <div>penicillin-sensitive</div> <div>staphylococci</div> <div>penicillin-resistant</div> </div> | <i>H. influenzae</i> | <i>E. coli</i> <i>Klebsiella</i> <i>Pseudomonas</i> |
| | penicillin | | | carbenicillin |
| | ampicillin/amoxicillin | | | ticarcillin |
| metronidazole | | | | |
| | | cloxacillin/methicillin | | |
| | | fusidic acid | | |
| | new-generation cephalosporins | | new-generation cephalosporins | |
| | | | gentamicin/tobramycin | |
| | erythromycin | | | amikacin |
| | clindamycin | | | |
| | cotrimoxazole; trimethoprim | | | |
| | | | chloramphenicol | |

Fig. 1.1. Suggested use of common antibiotics.

TOPICAL ANTIBIOTICS

The efficacy and safety of topical application of antibiotics for infections of the skin, nares and external ear have been brought into question. For mild local infections antiseptic agents are likely to be equally effective. In severe infections the low concentrations of antibiotic achieved are unlikely to be sufficient, and systemic treatment is necessary.

There is convincing evidence that the topical use of aminoglycosides and other antibiotics such as tetracyclines and fusidic acid contributes to bacterial resistance. Suboptimal concentrations lead to selection of bacterial variants with a capacity to inactivate the drug or reduce antibiotic penetration into the bacterial cell. There may be an abrupt one-step development of resistance as a result of acquisition of extra-chromosomal DNA (plasmids). The acquired microbial resistance towards one aminoglycoside is likely to be shared by other antibiotics of the group, and not uncommonly plasmid transfer confers multiple antibiotic resistance.

As a general principle, no antibiotic which is used systemically (or is closely related to one used systemically) is applied to the surface of the body.

The eye is an exception to these general considerations. The sequelae of ocular infections may be serious, and the organisms most feared in this respect are *Pseudomonas aeruginosa*, *Streptococcus pneumoniae* and penicillin-resistant staphylococci. The penetration of agents such as sulphacetamide, chloramphenicol and gentamicin (the latter injected subconjunctivally) enable high local concentrations to be achieved.

Certain antibiotics such as the peptides (bacitracin, polymyxins and tyrocidine), polyenes (nystatin and pimaricin) and clotrimazole are not significantly absorbed from the skin or mucous membranes. They are practically free of the problems of microbial resistance; this may be attributable in part to their limited use in practice.

BETA-LACTAMASES:

β -Lactamase was originally identified as the staphylococcal enzyme capable of destroying the β -lactam ring of the penicillin nucleus, thus rendering the antibiotic inactive. With the development

and widespread use of broad-spectrum, semi-synthetic penicillins and cephalosporins, penicillin- and cephalosporin-resistant Gram-negative bacteria emerged which produced a β -lactamase different to that of staphylococci. The latter is cell-bound, and confers a permeability barrier which protects the bacterial cell from antibiotic destruction. (The production of a β -lactamase in small amounts is a characteristic of many Gram-negative bacteria; it may be necessary for normal growth of the organism.)

Amongst the Gram-negative bacteria the β -lactamases can be broadly classified into:

- i) Those that preferentially hydrolyse penicillins with little anti-cephalosporin activity ("penicillinases").
- ii) Those that hydrolyse cephalosporins with little anti-penicillin activity ("cephalosporinases").
- iii) "Broad-spectrum" β -lactamases that hydrolyse both penicillins and cephalosporins to a considerable extent.

Most penicillinases destroy benzylpenicillin, penicillin V, ampicillin, amoxicillin and carbenicillin. No β -lactam antibiotic is completely resistant to the β -lactamases. The degree of penicillinase and cephalosporinase production of various micro-organisms is indicated in Table 1.2.

Table 1.2. β -Lactamase production by various micro-organisms

| | Penicillinase | Cephalosporinase ^a |
|-------------------------------|---------------|-------------------------------|
| <i>Staph. aureus</i> | ++++ | +++ →+ |
| <i>Ps. aeruginosa</i> | ++++ | ++ →+ |
| <i>Proteus sp.</i> | +++ | + →+ |
| <i>Haemophilus influenzae</i> | ++++ | +++ →+ |
| <i>Klebsiella sp.</i> | ++++ | ++ →+ |
| <i>Bacteroides fragilis</i> | ++++ | ++++ →+ |

^aThe cephalosporinases are less effective against the new-generation cephalosporins.

SIDE-EFFECTS

A distinction can be made between (a) dose-related adverse effects that are predictable from the pharmacological action and toxicity profile of an antibiotic or from biological effects due to growth inhibition of the normal bacterial flora, such as is

frequently encountered with broad-spectrum antibiotics, and (b) allergic reactions, which are dose-independent and in the main not predictable.

A profile of side-effects of different antibiotics and chemotherapeutic agents is given in Table 1.3.

Table 1.3. Side-effects of antibiotics and chemotherapeutic agents

| Antibiotic or chemotherapeutic agent | Side-effects | | | | | Contra-indicated or to be used with considerable caution in advanced renal insufficiency |
|--|-------------------|------------------|------------------|-------------|-------------------|--|
| | Allergic | Haemato-toxic | Nephrotoxic | Hepatotoxic | Neurotoxic | |
| Penicillin | ++ ⁽¹⁾ | | | | + | |
| Flucloxacillin; dicloxacillin | ++ | | | | ± | |
| Amoxicillin; ampicillin | ++ | | | | ± | |
| New cephalosporins | + ⁽¹⁾ | ± | | | | |
| Chloramphenicol | ± | + ⁽²⁾ | | | ± | |
| Aminoglycosides ⁽³⁾ | + | | + ⁽⁴⁾ | | ++ ⁽⁵⁾ | X |
| Tetracyclines | ± | ± | | ± | | X ⁽⁶⁾ |
| Erythromycin; clindamycin ⁽⁷⁾ | ± | | | ± | | |
| Fusidic acid | ± | | | | | |
| Vancomycin | ++ | | + | | + | X |
| Sulphonamides; cotrimoxazole | ++ | ± | ± | ± | | |

Key: ± = rare; + = uncommon; ++ = relatively frequent

Numbers refer to the following notes

Notes:

1. For discussion of allergic reactions to the penicillins and cephalosporins refer to p. 00.
2. Chloramphenicol depresses the bone marrow by one of two mechanisms:
 - i) A dose-related reversible effect mainly on the formation of red cells, but at times also platelets and granulocytes; and
 - ii) Severe aplasia with pancytopenia, which is uncommon, unpredictable, not dose-related, and idiosyncratic.

The former appears to be due to inhibition of mitochondrial protein synthesis. The latter probably results from a genetically determined biochemical predisposition (a defect in nucleic acid synthesis has been suggested).

3. The comparative toxicity of the aminoglycosides is set out below:

| Antibiotic | Effects on: | | | |
|---------------------|-------------|---------|--------|------------------------|
| | Vestibulum | Cochlea | Kidney | Neuromuscular blocking |
| Streptomycin | +++ | + | + | ++ |
| Dihydrostreptomycin | + | +++ | + | + |
| Neomycin | + | ++++ | +++ | +++ |
| Framycetin | + | ++++ | +++ | +++ |
| Kanamycin | + | +++ | ++ | +++ |
| Gentamicin | ++ | + | ++ | ++ |
| Tobramycin | ++ | + | ++ | ++ |

4. The risk of aminoglycoside nephrotoxicity is greater in the following circumstances: concomitant treatment with other potentially nephrotoxic antibiotics (e.g. vancomycin); treatment in excess of 10–14 days; serious coexistent disease such as coagulopathy, bleeding, shock, dehydration and urate nephropathy (in cancer patients on cytotoxic treatment).
5. The aminoglycosides destroy the sensory hair cells in the inner ear (organ of Corti of the cochlea). The risk of aminoglycoside ototoxicity is greater with concomitant use of high-ceiling diuretics, usage in excess of 10 days, renal disease with decompensation, high dosage, recent aminoglycoside therapy, pre-existing ear disease and in patients older than 40 years. Delayed ototoxicity may occur even after treatment has been discontinued. This is thought to be due to the persistent toxic effect of accumulated drug in the inner ear and semicircular canals. Unilateral aminoglycoside ototoxicity has been described. Topically administered aminoglycosides in the ear may account for some deafness complicating otitis media. Even the “non-absorbable” aminoglycosides such as neomycin can be absorbed from the gastrointestinal tract or following intrabronchial or intraperitoneal administration in sufficient amounts to cause deafness. This is likely when there is coexistent renal insufficiency and the antibiotic cannot be normally eliminated.
6. Doxycycline can be administered in renal insufficiency, although appropriate dosage adjustments are necessary in advanced failure (see Table 1.4), and because of poor filtration into the urine it is unlikely to be effective in urinary tract infections in such patients. (Between 60% and 70% of the other tetracyclines is excreted in the urine; 35%–40% of a dose of doxycycline is excreted in the urine.)
7. A serious potential side-effect of clindamycin therapy is pseudomembranous colitis.

RENAL ELIMINATION

Many antimicrobial agents are eliminated primarily by the kidneys. The aminoglycosides, the polymyxins and vancomycin are exclusively eliminated by renal mechanisms and their toxicity correlates directly with concentrations in plasma and tissues. Since the adverse effects of these antibiotics involve the kidneys a vicious cycle may develop if they accumulate in the body.

Tetracyclines accumulate in patients with impaired renal function, with the exception of doxycycline. Uraemia may be aggravated by the catabolic effect of elevated amounts of tetracycline.

A guideline for dosage adjustments for patients in renal failure is given in Table 1.4.

HEPATIC DISEASE AND FAILURE

The dosage of antibiotics excreted by the liver (erythromycin, chloramphenicol, lincomycin, clindamycin and doxycycline) must be reduced in patients with hepatic failure.

If there is infection in the biliary tract, hepatic disease or biliary obstruction may reduce access of an antibiotic to the site of the infection. This has been shown to occur with several drugs normally excreted in the bile.